FOLR1 and ovarian carcinoma: In epithelial ovarian cancer (EOC), several promising preclinical CAR constructs directed against Folate Binding Protein, MUC-1, mesothelin and Lewis-Y antigens have been reported (Carpenito et al., 2009; Kershaw et al., 2002; Parker et al., 2000; Wang et al., 1998; Westwood et al., 2005; Wilkie et al., 2008), yet none of these have led to any significant clinical benefits.